[1]覃端,田耘,史健.肾复康Ⅱ号联合氯沙坦钾对IgAN伴肾小管间质纤维化患者尿蛋白定量与中医证候积分的影响[J].西部中医药,2024,37(01):135-138.[doi:10.12174/j.issn.2096-9600.2024.01.27]
 QIN Duan,TIAN Yun,SHI Jian.Effects of Shenfukang II and Losartan Potassium on Urine Protein Quantification and TCM Syndrome Integrals in Patients with IgAN and Tubulointerstitial Fibrosis[J].Western Journal of Traditional Chinese Medicine,2024,37(01):135-138.[doi:10.12174/j.issn.2096-9600.2024.01.27]
点击复制

肾复康Ⅱ号联合氯沙坦钾对IgAN伴肾小管间质纤维化患者尿蛋白定量与中医证候积分的影响
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年01期
页码:
135-138
栏目:
衷中参西
出版日期:
2024-01-15

文章信息/Info

Title:
Effects of Shenfukang II and Losartan Potassium on Urine Protein Quantification and TCM Syndrome Integrals in Patients with IgAN and Tubulointerstitial Fibrosis
作者:
覃端1, 田耘2, 史健2
1.陕西中医药大学第一临床医学院,陕西 咸阳 712046
2.陕西省中医医院肾病一科,陕西 西安 710003
Author(s):
QIN Duan1, TIAN Yun2, SHI Jian2
1.First Clinical Medical School, Shaanxi University of Chinese Medicine, Xianyang 712046, China
2.First Nephropathy Department, Shaanxi Provincial TCM Hospital, Xi'an 710003, China
关键词:
免疫球蛋白A肾病间质纤维化尿蛋白定量中医证候肾复康Ⅱ号氯沙坦钾
Keywords:
IgANtubulointerstitial fibrosisurine protein quantificationTCM syndrome integralsIIlosartan potassium
分类号:
R259
DOI:
10.12174/j.issn.2096-9600.2024.01.27
文献标志码:
B
摘要:
目的探讨肾复康Ⅱ号胶囊联合氯沙坦钾片对免疫球蛋白A肾病(immunoglobulin A nephropathy,IgAN)伴肾小管间质纤维化患者尿蛋白定量与中医证候积分的影响及其相关性。 方法将80例IgAN伴肾小管间质纤维化患者分为对照组和试验组各40例,对照组予氯沙坦钾片治疗,试验组在对照组基础上予肾复康Ⅱ号胶囊,观察两组患者治疗12、24周后尿蛋白定量及治疗前后中医证候积分。 结果与治疗前比较,试验组治疗12、24周后尿蛋白定量下降(P<0.05),对照组治疗24周尿蛋白定量下降(P<0.05);与对照组比较,试验组治疗12、24周尿蛋白定量降低(P<0.05);治疗24周后试验组中医证候积分较治疗前降低(P<0.05)。 结论IgAN伴肾小管间质纤维化患者尿蛋白定量与中医证候积分之间存在相关性,尿蛋白定量及预后与中医证候、总有效率具有一致性。
Abstract:
ObjectiveTo explore the influence of Shenfukang II and losartan potassium on urine protein quantification and TCM syndrome integrals in patients with IgAN and tubulointerstitial fibrosis and its relationship. MethodsEighty IgAN patients with tubulointerstitial fibrosis were allocated to the control group and the experiment group with 40 cases in each group, the control group was treated by Losartan Potassium tablets, and the experiment group was given Shenfukang II on the foundation of Western medicine, after 12 and 24 weeks of the treatment, to observe urine protein quantification and TCM syndrome integrals before and after the treatment. ResultsCompared with before treating, urine protein quantification was decreased in the experiment group after 12 and 24 weeks of treatment (P<0.05), urine protein quantitative was lowered after 24 weeks of treatment in the control group (P<0.05); Compared with the control group, urine protein quantification was reduced in the experiment group after 12 and 24 weeks of treatment (P<0.05). TCM syndrome integrals were reduced in the experiment group after 24 weeks of treatment (P<0.05). ConclusionUrine protein quantification is related to TCM syndrome integrals in patients with IgAN and tubulointerstitial fibrosis, urine protein quantification and the prognosis are consistent with TCM syndromes and total effective rate.

备注/Memo

备注/Memo:
覃端(1995—),女,硕士学位。研究方向:肾病的中医药防治。国家自然科学基金(81774123);陕西省科技研发计划(S2018-YF-YBSF-0818)。
更新日期/Last Update: 2024-01-15